PriceTargets.com logo

Neovasc - NVCN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$30.03 As of 04/11/2023 01:00 AM ET
+0 (0.00%)
Get New Neovasc Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NVCN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NVCN

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Neovasc in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $30.03.

This chart shows the closing price for NVCN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Neovasc. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2023Bloom BurtonDowngradeBuy ➝ HoldLow
1/18/2023HC WainwrightDowngradeBuy ➝ NeutralLow
8/12/2022Bloom BurtonReiterated RatingBuyLow
3/11/2022HC WainwrightReiterated RatingBuy$125.00High
12/1/2021HC WainwrightReiterated RatingBuy$125.00High
3/14/2021SVB LeerinkReiterated RatingBuy$50.00High
11/6/2020SVB LeerinkLower TargetOutperform$150.00 ➝ $50.00High
8/20/2020SVB LeerinkReiterated RatingOutperform ➝ Market Perform$150.00High
7/2/2020HC WainwrightReiterated RatingBuy$125.00N/A
5/8/2020HC WainwrightReiterated RatingBuy$225.00 ➝ $125.00Medium
4/14/2020Noble FinancialInitiated CoverageOutperform$375.00High
11/4/2019HC WainwrightSet TargetBuy$225.00Medium
10/24/2019HC WainwrightInitiated CoverageBuy$225.00High
(Data available from 4/26/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Neovasc logo
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. It focuses on Neovast Tiara and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
Read More

Today's Range

Now: $30.03
Low: $30.03
High: $30.03

50 Day Range

MA: $29.69
Low: $29.03
High: $30.03

52 Week Range

Now: $30.03
Low: $4.59
High: $30.07

Volume

1 shs

Average Volume

56,993 shs

Market Capitalization

$82.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Neovasc?

The following sell-side analysts have issued reports on Neovasc in the last year: StockNews.com.
View the latest analyst ratings for NVCN.

What is the current price target for Neovasc?

0 Wall Street analysts have set twelve-month price targets for Neovasc in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Neovasc in the next year.
View the latest price targets for NVCN.

What is the current consensus analyst rating for Neovasc?

Neovasc currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for NVCN.

What other companies compete with Neovasc?

Other companies that are similar to Neovasc include BrainsWay, Allurion Technologies, enVVeno Medical, Monogram Orthopaedics and BlueRiver Acquisition. Learn More about companies similar to Neovasc.

How do I contact Neovasc's investor relations team?

Neovasc's physical mailing address is Suite 5138 - 13562 Maycrest Way, RICHMOND A1, V6V 2J7. The medical equipment provider's listed phone number is (604) 270-4344 and its investor relations email address is [email protected]. The official website for Neovasc is www.neovasc.com. Learn More about contacing Neovasc investor relations.